All In Biotech

Drug Trial Radar · NCT07904689

A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 1, Two-Part, First-in-Human, Randomized, Blinded, Placebo-Controlled, Single and Multiple Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NOR-101 in Healthy Participants and Participants With Moderate-to-Severe Atopic Dermatitis.

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2030

Study completion Jan 2030

Sponsor

Lead sponsor
North Immunology Inc.Industry
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study will assess NOR-101, an investigational study drug, in two parts. Part 1 is a randomized, blinded study comparing single and multiple doses of NOR-101 with placebo in healthy adults. A placebo is a look-alike substance containing no active drug. Part 2 is an open-label, multiple-dose study in adults with moderate-to-severe atopic dermatitis (eczema). All participants in Part 2 will receive NOR-101.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • NOR-101Drug

    NOR-101 will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From informed consent through the end of the trial (EOT), up to approximately 29 months.
  2. Number of participants with clinically significant vital sign abnormalitiesTime frame: Baseline through 12 months after the last dose (up to approximately 20 months).
  3. Number of participants with clinically significant electrocardiogram abnormalitiesTime frame: Baseline through 12 months after the last dose (up to approximately 20 months).
  4. Number of participants with clinically significant clinical laboratory abnormalitiesTime frame: Baseline through 12 months after the last dose (up to approximately 20 months).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.